GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Concord Drugs Ltd (BOM:538965) » Definitions » E10

Concord Drugs (BOM:538965) E10 : ₹1.72 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Concord Drugs E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Concord Drugs's adjusted earnings per share data for the three months ended in Dec. 2024 was ₹0.230. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹1.72 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Concord Drugs's average E10 Growth Rate was -2.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-04-02), Concord Drugs's current stock price is ₹32.39. Concord Drugs's E10 for the quarter that ended in Dec. 2024 was ₹1.72. Concord Drugs's Shiller PE Ratio of today is 18.83.

During the past 11 years, the highest Shiller PE Ratio of Concord Drugs was 29.25. The lowest was 17.76. And the median was 21.65.


Concord Drugs E10 Historical Data

The historical data trend for Concord Drugs's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Drugs E10 Chart

Concord Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.72

Concord Drugs Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 1.72 1.73 1.72 1.72

Competitive Comparison of Concord Drugs's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Drugs's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Concord Drugs's Shiller PE Ratio falls into.


;
;

Concord Drugs E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Concord Drugs's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.23/158.3229*158.3229
=0.230

Current CPI (Dec. 2024) = 158.3229.

Concord Drugs Quarterly Data

per share eps CPI Adj_EPS
201503 0.450 97.163 0.733
201506 0.310 99.841 0.492
201509 0.340 101.753 0.529
201512 2.580 102.901 3.970
201603 0.730 102.518 1.127
201606 0.160 105.961 0.239
201609 0.480 105.961 0.717
201612 1.830 105.196 2.754
201703 -2.450 105.196 -3.687
201706 -0.010 107.109 -0.015
201709 0.080 109.021 0.116
201712 0.410 109.404 0.593
201803 -0.170 109.786 -0.245
201806 0.160 111.317 0.228
201809 0.050 115.142 0.069
201812 0.050 115.142 0.069
201903 0.260 118.202 0.348
201906 0.150 120.880 0.196
201909 0.060 123.175 0.077
201912 0.050 126.235 0.063
202003 0.110 124.705 0.140
202006 0.190 127.000 0.237
202009 0.092 130.118 0.112
202012 3.090 130.889 3.738
202103 0.386 131.771 0.464
202106 0.790 134.084 0.933
202109 0.520 135.847 0.606
202112 0.480 138.161 0.550
202203 0.030 138.822 0.034
202206 0.210 142.347 0.234
202209 0.210 144.661 0.230
202212 0.520 145.763 0.565
202303 0.120 146.865 0.129
202306 0.530 150.280 0.558
202309 0.600 151.492 0.627
202312 -0.240 152.924 -0.248
202403 -0.340 153.035 -0.352
202406 0.030 155.789 0.030
202409 0.040 157.882 0.040
202412 0.230 158.323 0.230

Add all the adjusted EPS together and divide 10 will get our e10.


Concord Drugs  (BOM:538965) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Concord Drugs's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=32.39/1.72
=18.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Shiller P/E Ratio of Concord Drugs was 29.25. The lowest was 17.76. And the median was 21.65.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Concord Drugs E10 Related Terms

Thank you for viewing the detailed overview of Concord Drugs's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Concord Drugs Business Description

Traded in Other Exchanges
N/A
Address
Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.

Concord Drugs Headlines

No Headlines